• DeutschDeutsch
  • EnglishEnglish
    • ABOUT
    • ONCOLOGY
    • PRODUCT
    • NEWS
    • INQUIRIES
    • VISIT US

Warning: Use of undefined constant simple_breadcrumb - assumed 'simple_breadcrumb' (this will throw an Error in a future version of PHP) in /homepages/43/d33652654/htdocs/wordpress/wp-content/themes/oncoscience2016/archive.php on line 3

ARCHIVES

  • June 2022
  • May 2022
  • November 2020
  • March 2019
  • October 2018
  • November 2017
  • August 2017
  • April 2016
  • July 2015
  • July 2010
  • October 2009
  • October 2008
  • April 2008
  • October 2007
  • September 2007
  • June 2007
  • September 2005
  • March 2005
  • January 2005
  • October 2004
  • August 2004
  • June 2004
  • March 2004
  • November 2003

SEARCH

  • The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively

    Oncoscience | October 26th, 2007

    The application for marketing authorization of Theraloc® (Nimotuzumab) was submitted to EMEA on October 4th, 2007. Aft...

  • Oncoscience AG reports marketing authorization approval for Theraloc® (Nimotuzumab) in the Ukraine

    Oncoscience | October 13th, 2007

    On October 12th, 2007 Theraloc® was approved in the Ukraine by the Ministry of Health of Ukraine. As of now Theraloc®...

  • Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer

    Oncoscience | September 12th, 2007

    Clearance Received for Two Additional Late-Stage Trials in Adult Glioma and Pancreatic Cancer Today Oncoscience AG (Wed...

  • Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy

    Oncoscience | June 8th, 2007

    Final results of the Phase II trial were described in an oral presentation at the Annual Meeting of the American Society...

    • LEGAL NOTICE

©Copyright of Oncoscience GmbH 2023

Diese Website benutzt Cookies. Wenn du die Website weiter nutzt, gehen wir von deinem Einverständnis aus.OKDatenschutzerklärung